Literature DB >> 32692932

Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through α2β1 Integrin.

Manisha Agarwal1, Mitchell Goheen1, Shijing Jia1, Song Ling1, Eric S White1, Kevin K Kim1.   

Abstract

Fibrosis is characterized by fibroblast activation, leading to matrix remodeling culminating in a stiff, type I collagen-rich fibrotic matrix. Alveolar epithelial cell (AEC) apoptosis is also a major feature of fibrogenesis, and AEC apoptosis is sufficient to initiate a robust lung fibrotic response. TGF-β (transforming growth factor-β) is a major driver of fibrosis and can induce both AEC apoptosis and fibroblast activation. We and others have previously shown that changes in extracellular matrix stiffness and composition can regulate the cellular response to TGF-β. In the present study, we find that type I collagen signaling promotes TGF-β-mediated fibroblast activation and inhibits TGF-β-induced AEC death. Fibroblasts cultured on type I collagen or fibrotic decellularized lung matrix had augmented activation in response to TGF-β, whereas AECs on cultured on type I collagen or fibrotic lung matrix were more resistant to TGF-β-induced apoptosis. Both of these responses were mediated by integrin α2β1, a major collagen receptor. AECs treated with an α2 integrin inhibitor or with deletion of α2 integrin had loss of collagen-mediated protection from apoptosis. We found that mice with fibroblast-specific deletion of α2 integrin were protected from fibrosis whereas mice with AEC-specific deletion of α2 integrin had more lung injury and a greater fibrotic response to bleomycin. Intrapulmonary delivery of an α2 integrin-activating collagen peptide inhibited AEC apoptosis in vitro and in vivo and attenuated the fibrotic response. These studies underscore the need for a thorough understanding of the divergent response to matrix signaling.

Entities:  

Keywords:  apoptosis; collagen; integrin

Mesh:

Substances:

Year:  2020        PMID: 32692932      PMCID: PMC7605165          DOI: 10.1165/rcmb.2020-0150OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  62 in total

1.  SFTPC mutations in patients with familial pulmonary fibrosis: combined with emphysema?

Authors:  Vincent Cottin; Jean-François Cordier
Journal:  Am J Respir Crit Care Med       Date:  2011-04-15       Impact factor: 21.405

2.  Researchers identify mutations in familial pulmonary fibrosis.

Authors:  Hilary Marshall
Journal:  Lancet Respir Med       Date:  2015-05-13       Impact factor: 30.700

Review 3.  Collagen-binding proteins: insights from the Collagen Toolkits.

Authors:  Richard W Farndale
Journal:  Essays Biochem       Date:  2019-09-13       Impact factor: 8.000

4.  Activated alveolar epithelial cells initiate fibrosis through secretion of mesenchymal proteins.

Authors:  Jibing Yang; Sarah E Wheeler; Miranda Velikoff; Kathryn R Kleaveland; Michael J LaFemina; James A Frank; Harold A Chapman; Paul J Christensen; Kevin K Kim
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

5.  Loss of myeloid-specific protein phosphatase 2A enhances lung injury and fibrosis and results in IL-10-dependent sensitization of epithelial cell apoptosis.

Authors:  Lei Sun; Elissa M Hult; Timothy T Cornell; Kevin K Kim; Thomas P Shanley; Carol A Wilke; Manisha Agarwal; Stephen J Gurczynski; Bethany B Moore; Mary K Dahmer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-03-06       Impact factor: 5.464

Review 6.  TGF-β1 Signaling and Tissue Fibrosis.

Authors:  Kevin K Kim; Dean Sheppard; Harold A Chapman
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

7.  Fibrotic extracellular matrix activates a profibrotic positive feedback loop.

Authors:  Matthew W Parker; Daniel Rossi; Mark Peterson; Karen Smith; Kristina Sikström; Eric S White; John E Connett; Craig A Henke; Ola Larsson; Peter B Bitterman
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

8.  Fibrocytes are not an essential source of type I collagen during lung fibrosis.

Authors:  Kathryn R Kleaveland; Miranda Velikoff; Jibing Yang; Manisha Agarwal; Richard A Rippe; Bethany B Moore; Kevin K Kim
Journal:  J Immunol       Date:  2014-10-03       Impact factor: 5.422

9.  Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth.

Authors:  Meghan C Brown; Izabela Staniszewska; Luis Del Valle; George P Tuszynski; Cezary Marcinkiewicz
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

10.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

View more
  2 in total

Review 1.  Update in Interstitial Lung Disease 2020.

Authors:  Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg
Journal:  Am J Respir Crit Care Med       Date:  2021-06-01       Impact factor: 21.405

2.  X-Linked Osteogenesis Imperfecta Possibly Caused by a Novel Variant in PLS3.

Authors:  Petar Brlek; Darko Antičević; Vilim Molnar; Vid Matišić; Kristina Robinson; Swaroop Aradhya; Dalibor Krpan; Dragan Primorac
Journal:  Genes (Basel)       Date:  2021-11-23       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.